VASCERN HHT Statement on COVID-19

A statement from the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN) for people with hereditary haemorrhagic telangiectasia (HHT) and their doctors:

1. People with HHT should follow the standard Public Health Measures as recommended in their specific country.
   1.1. These are directed at reducing the spread of infection, and strategies differ slightly between countries.

2. People with HHT should be no more and no less concerned about COVID-19 than the general population without HHT.
   2.1. There is no reason to think people with HHT [1] will be at higher or lower risk of infection [2,3], or complications if they become infected.
   2.2. Some people with HHT, as for some people in the general population, may be less able to tolerate the extra demands placed on their bodies if they suffer infection with complications, but this will be a small group and should not be applied to all HHT patients.

3. The presence of HHT or AVMs in someone who currently has a normal or high exercise tolerance should not limit their access to medical treatment compared to someone without HHT or AVMs of the same age.
   3.1. People with HHT have normal life expectancy managed in Europe,[4,5] likely attributed to the beneficial effects of reduced cancer, reduced rates of cancer [4,6,7] and fewer heart attacks [8]
   3.2. Anyone with normal or high exercise tolerance (able to walk uphill quite briskly without stopping) will have good cardiorespiratory reserve [9,10].

4. For those who are obliged to self-isolate because of the general situation
   4.1. Maintain normal treatment regimes if possible.
   4.2. Avoid sedentary states- exercise is recommended as discussed further for the general population [11]

AUTHORS:
Claire L. Shovlin, Carlo Sabha, Hans Jurgen Mager, Anette Kjeldsen, Ulrich Sure, Elisabetta Buscarini and Sophie Dupuis-Girod
VASCERN HHT Centre Leads in Denmark, France, Germany, Italy, the Netherlands and the UK, on behalf of VASCERN HHT

Further reading if required:

General HHT:

Infection/Viral infection
[3] VASCERN HHT Prophylactic antibiotics, the pulmonary capillaries, and vaccination in HHT http://www.haematologica.org/content/104/2/e85.long/

Survival/life expectancy:

Exercise, compensations and conditioning - with specific reference to normal capacity despite hypoxaemia from pulmonary AVMs

https://vascern.eu/expertise/rare-diseases-wgs/hht-wg/